Objectives:

1. To discuss incidence of germline mutations identified in next-generation sequencing platforms
2. To review currently available data regarding relevance of germline mutations to metastatic disease
3. To discuss management strategies for incidental germline findings

and

1. Review CML treatment with tyrosine kinase inhibitors, including disease monitoring
2. Understand the potential harms of tyrosine kinase inhibitors on fertility
3. Discuss optimal management of CML during pregnancies